

学校编码: 10384

分类号 _____ 密级 _____

学号: 24520121153236

UDC _____

厦 门 大 学

硕 士 学 位 论 文

绿原酸-栀子苷组合调控非酒精性脂肪性肝病剂量配比优化研究

Optimization Dosage Study of the Combination of Chlorogenic and Geniposide on Non-alcoholic Fatty Liver Disease

赵道

指导教师姓名: 周海虹 教授

专 业 名 称: 中医内科学

论文提交日期: 2015 年 4 月

论文答辩日期: 2015 年 5 月

2015 年 5 月

厦门大学博硕士学位论文摘要库

厦门大学学位论文原创性声明

本人呈交的学位论文是本人在导师指导下,独立完成的研究成果。本人在论文写作中参考其他个人或集体已经发表的研究成果,均在文中以适当方式明确标明,并符合法律规范和《厦门大学研究生学术活动规范(试行)》。

另外,该学位论文为()课题(组)的研究成果,获得()课题(组)经费或实验室的资助,在()实验室完成。(请在以上括号内填写课题或课题组负责人或实验室名称,未有此项声明内容的,可以不作特别声明。)

声明人(签名):

年 月 日

厦门大学学位论文著作权使用声明

本人同意厦门大学根据《中华人民共和国学位条例暂行实施办法》等规定保留和使用此学位论文，并向主管部门或其指定机构送交学位论文（包括纸质版和电子版），允许学位论文进入厦门大学图书馆及其数据库被查阅、借阅。本人同意厦门大学将学位论文加入全国博士、硕士学位论文共建单位数据库进行检索，将学位论文的标题和摘要汇编出版，采用影印、缩印或者其它方式合理复制学位论文。

本学位论文属于：

（ ） 1.经厦门大学保密委员会审查核定的保密学位论文，
于 年 月 日解密，解密后适用上述授权。

（ ） 2.不保密，适用上述授权。

（请在以上相应括号内打“√”或填上相应内容。保密学位论文应是已经厦门大学保密委员会审定过的学位论文，未经厦门大学保密委员会审定的学位论文均为公开学位论文。此声明栏不填写的，默认为公开学位论文，均适用上述授权。）

声明人（签名）：

年 月 日

摘要

目的：本研究通过运用数学模型均匀设计法，观察中药有效成分绿原酸、栀子苷配伍使用对高脂饮食诱导非酒精性脂肪性肝病（NAFLD）大鼠模型所产生的药理效应。并从多角度指标分析绿原酸、栀子苷对 NAFLD 脂质代谢紊乱、肝脏炎症损伤病理状态的影响，筛选出绿原酸-栀子苷组合抗 NAFLD 的最优剂量配比，探索中药复方治疗 NAFLD 的药效基础。

方法：1、均匀设计筛选实验：55 只雄性 Wistar 大鼠，随机分为正常组、造模组。正常组普通饲料喂养，造模组采用改良高脂饲料饮食 8 周诱导 NAFLD 大鼠模型。造模组自第 5 周开始随机分为模型组和 6 组药物组。药物组以绿原酸、栀子苷作为考察因子，选用 U^6 (6^4) 均匀表进行组方设计，所得 6 组绿原酸-栀子苷组合水平为各药组所对应 100g 大鼠每日给药量。4 周用药结束后，观察记录各组大鼠一般情况（体重、肝湿重、脂肪重量、肝指数），并检测脂质代谢（肝组织 TG、血清 CHO、LDL-C、HDL-C）、炎症损伤（血清 ALT、AST）等相关指标。采用多元逐步回归方法分析针对不同指标的效应成分，筛选出抗 NAFLD 的绿原酸-栀子苷组合最优剂量配比。

2、验证实验：根据筛选实验综合分析所得绿原酸-栀子苷最优配比组合，并设正常组、模型组、绿原酸组、栀子苷组、血脂康组、绿原酸-栀子苷最佳剂量配比组进行对比，再次使用上述方法造模，以验证观察实验结果，观察指标同筛选实验。

结果：1、均匀设计筛选实验：模型组大鼠体重、肝湿重、脂肪重量、肝指数、肝组织 TG、血清 CHO、LDL-C、ALT、AST 均较正常组大鼠升高，血清 HDL-C 较正常组降低 ($P<0.05$)，提示高脂饮食诱导 NAFLD 模型成功。药物组各指标较模型组有不同程度改善，经优化指标综合分析筛选得出最佳剂量配比为绿原酸、栀子苷各 90mg。

2、验证实验：与模型组比较，绿原酸-栀子苷最优剂量配比组可显著降低 NAFLD 大鼠模型肝组织 TG、血清 CHO、LDL-C 水平，升高血清 HDL-C 水平，降低血清 ALT、AST 活性，改善 NAS 活动积分 ($P<0.05$)。与其它治疗组比较，

最优剂量配比组肝组织病理学结果优于绿原酸组、栀子苷组与血脂康组；降低模型体重、脂肪重量优于绿原酸组、血脂康组；降低肝指数优于栀子苷组；降低血清 CHO 水平优于血脂康组；降低血清 ALT 活性优于绿原酸组；NAS 积分明显低于绿原酸组（ $P<0.05$ ）；

结论：1、通过改良后的高脂饮食，可以成功诱导NAFLD大鼠模型。

2、运用数学模型均匀设计法可以较准确地优化中药复方中两个以上有效成分的剂量配比。

3、中药有效成分绿原酸、栀子苷配伍使用具有降低肝组织TG、血清CHO、LDL-C水平，降低血清ALT、AST活性，提高血清HDL-C水平的药理效应，两种中药有效成分在调节以上指标中具有明显的交互效应，其最优剂量配比为绿原酸、栀子苷各90mg。

4、经均匀设计法筛选出的绿原酸-栀子苷组合最优剂量配比，能有效地改善高脂饮食诱导NAFLD大鼠模型脂质代谢异常和炎症损伤的病理状态，其综合药理学效应较单独应用同等剂量绿原酸组、栀子苷与常规剂量的血脂康更为明显。

关键词：非酒精性脂肪性肝病 均匀设计法 绿原酸 栀子苷 绿原酸-栀子苷组合

Abstract

Objective: To observe the effects of the combination of chlorogenic acid and geniposide, which are effective components of Chinese medicine, on experimental rat model of Non-alcoholic fatty liver disease (NAFLD) induced by high fat diet, we applied uniform design method to establish the mathematical model. What's more, we chose multi-angle indexes to analyse the effects of chlorogenic acid and geniposide on the lipid metabolism and inflammation injury of NAFLD, in order to screen the optimal dosage proportion of the combination of chlorogenic acid and geniposide. By these measures above, we hope to find the pharmacodynamics basis of prescription of Chinese medicine related to NAFLD.

Methods: 1. Uniform design screening experiment: 55 male Wistar rats were randomly divided into normal group and model group. Normal group were fed with normal fodder during all the experiment. Meanwhile, model group were fed with improved high fat diet for 8 weeks and divided into original model group and 6 treatment groups at the beginning of 5th week. We arranged 6 levels of combination of chlorogenic acid and geniposide as the daily dosage per 100 grams of rat weights on 6 treatment groups, according to the table $U_6(6^4)$ of uniform design. After the rats were killed, their body weight, liver weight, fat weight and liver index were recorded. Furthermore, their blood and livers were collected for research. The indexes which need to test including: levels of liver TG, serum CHO, LDL-C, HDL-C and activities of serum ALT, AST. All the indexes above were analyzed by multiple stepwise regression to screen the optimal dosage proportion of the combination of chlorogenic acid and geniposide to treat NAFLD.

2. Verification experiment: To verify the optimal dosage proportion of the combination of chlorogenic acid and geniposide to treat NAFLD from screening experiment, we establish the rats model of NAFLD as before. And building the normal group, model group, chlorogenic acid group, geniposide group and Xuezhikang group

to compare the therapeutic effect with the optimal dose proportion. Testing indexes are same as screening experiment.

Results:1. Uniform design screening experiment: In comparison with the normal group, the model group's body weight, liver weight, fat weight, liver index, levels of liver TG, serum CHO, LDL-C, ALT, AST are increased significantly, and serum HDL-C are decreased significantly ($P < 0.05$). It implied the model of NAFLD is successful. In comparison with model group, the indexes of 6 treatment groups improved more or less. By comprehensive analysis of every index, the optimal dosage proportion is 90mg chlorogenic acid and 90mg geniposide.

2. Verification experiment: In comparison of model group, the optimal dose proportion group can obviously improve the indexes of liver TG, serum CHO, LDL-C, HDL-C, ALT, AST and NAS ($P < 0.05$). In comparison of other treatment groups, the optimal dosage proportion group has a better liver tissue pathological results, which is better than chlorogenic acid group and Xuezhikang group in body weight and fat weight as well. Moreover, the optimal dosage proportion group decreased more significantly in liver index than geniposide group, while it also has a superiority in decreasing more in serum CHO than Xuezhikang group, which is also better than both reducing the activity of serum ALT and NAS in chlorogenic acid group ($P < 0.05$).

Conclusions:1. Improved high fat diet can induce rat model of NAFLD successfully.

2. Mathematical model of uniform design can screen the optimal dose proportion of two or more effective components of Chinese medicine prescription.

3. The combination of chlorogenic acid and geniposide has a significant pharmacological effect of decreasing levels of liver TG, serum CHO, LDL-C, activities of serum ALT, AST and increasing level of serum HDL-C. Besides, there has a outstanding interaction in the above indexes. The optimal dosage proportion is 90mg chlorogenic acid and 90mg geniposide.

4. The optimal dosage proportion of chlorogenic acid and geniposide, from uniform design screening, has a significant pharmacological effect on rat model of NAFLD induced by high fat diet. It can availablely improve the pathological state of

NAFLD, especially in the field of lipid metabolism and inflammation injury. Meanwhile, its comprehensive pharmacological effect is superior to separate chlorogenic acid group, separate geniposide group or Xuezhikang group.

Keywords: Non-alcoholic fatty liver disease; Uniform design; Chlorogenic acid; Geniposide; The combination of Chlorogenic acid and geniposide

厦门大学博硕士学位论文摘要库

目 录

摘 要	I
Abstract	III
前言	1
1 现代医学对非酒精性脂肪性肝病的认识.....	1
1.1 非酒精性脂肪性肝病概述.....	1
1.3 非酒精性脂肪性肝病的治疗.....	2
2 中医药对非酒精性脂肪性肝病的认识.....	4
2.1 非酒精性脂肪性肝病的病因病机及辨证分型.....	4
2.2 中药复方治疗非酒精性脂肪性肝病概况.....	5
2.3 中药复方有效组分的研究.....	6
3 中药有效成分绿原酸、栀子苷治疗非酒精性脂肪性肝病.....	7
3.1 绿原酸具有防治非酒精性脂肪性肝病的药理效应.....	7
3.2 栀子苷具有防治非酒精性脂肪性肝病的药理效应.....	8
3.3 本课题的前期工作积累.....	8
4 均匀设计法可用于中药有效组分剂量筛选.....	9
第一部分 基于均匀设计的绿原酸-栀子苷最优剂量配比筛选实验	11
材料与方 法	11
1 实验材料.....	11
1.1 实验动物.....	11
1.2 实验药物.....	11
1.3 动物饲料.....	11
1.4 主要试剂.....	11
1.5 主要仪器.....	12
1.6 其他设备及耗材.....	12
2 实验方法.....	13
2.1 模型制备.....	13

2.2 均匀设计实验分组.....	13
2.3 实验用药.....	14
2.4 标本留取方法.....	15
2.5 肝组织 TG 检测.....	15
2.5.1 肝组织匀浆标本制备.....	15
2.6 血清脂质代谢相关指标检测.....	16
2.6.1 血清 CHO 含量测定（酶法）.....	16
2.6.2 血清 LDL-C 含量测定（选择性沉淀法）.....	16
2.6.3 血清 HDL-C 含量测定（选择性沉淀法）.....	17
2.7 血清炎症损伤相关指标检测.....	18
2.7.1 血清 ALT 活性测定（赖氏法）.....	18
2.8 肝组织病理 HE 染色.....	20
2.9 统计处理.....	20
结果.....	22
1 各组大鼠一般情况的评估.....	22
2 各组大鼠体重、肝重与脂肪重量的变化.....	22
3 各组大鼠肝指数的变化.....	23
4 正常组、模型组大鼠肝脏外观表现.....	23
5 正常组、模型组大鼠肝组织病理 HE 染色的变化.....	24
6 各组大鼠脂质代谢相关指标的结果.....	24
7 各组大鼠血清炎症损伤相关指标的变化.....	26
8 均匀设计实验结果分析.....	27
8.1 以肝组织 TG 为因变量进行多元逐步回归及结果分析.....	27
8.2 以血清 ALT 为因变量进行多元逐步回归及结果分析.....	29
8.3 以血清 AST 为因变量进行多元逐步回归及结果分析.....	30
8.4 以血清 CHO 为因变量进行多元逐步回归及结果分析.....	31
8.5 以血清 LDL-C 为因变量进行多元逐步回归及结果分析.....	32
8.6 以血清 HDL-C 为因变量进行多元逐步回归及结果分析.....	33
8.7 以大鼠体重为因变量进行多元逐步回归及结果分析.....	34
8.8 以大鼠肝湿重为因变量进行多元逐步回归及结果分析.....	35
8.9 以大鼠脂肪重量为因变量进行多元逐步回归及结果分析.....	36
8.10 以大鼠肝体比为因变量进行多元逐步回归及结果分析.....	36

8.11 均匀设计筛选实验各指标回归结果综合分析.....	36
讨 论.....	37
1 非酒精性脂肪性肝病动物模型建立的思路.....	37
2 中药复方配伍的内涵.....	38
3 中药复方有效组分的研究方法.....	39
4 均匀设计法用于中药复方有效组分研究的合理性分析.....	40
5 运用均匀设计法筛选绿原酸-栀子苷最优剂量配比.....	41
第二部分 均匀设计筛选所得绿原酸-栀子苷组合最优剂量配比的验证实验.....	43
材料和方法.....	43
1 实验材料.....	43
1.1 实验动物.....	43
1.2 实验药物.....	43
1.3 动物饲料.....	43
1.4 主要试剂.....	43
1.5 主要仪器.....	43
1.6 其他设备及耗材.....	43
2.1 模型制备.....	44
2.2 分组.....	44
2.4 标本留取方法.....	44
2.5 肝组织 TG 检测.....	44
2.6 血清脂质代谢指标检测.....	45
2.7 血清炎症损伤相关指标检测.....	45
2.8 肝组织病理染色.....	45
2.9 统计处理.....	45
结 果.....	46
1 各组大鼠一般情况的评估.....	46
2 各组大鼠体重、肝重与脂肪重量的变化.....	46
3 各组大鼠肝指数的变化.....	47
4 各组大鼠肝脏外观表现.....	47
5 各组大鼠脂质代谢相关指标的变化.....	48

6 各组大鼠血清炎症损伤相关指标的变化.....	49
7 各组大鼠肝组织病理变化.....	50
7.1 各组大鼠肝组织病理 HE 染色的变化.....	50
7.2 各组大鼠肝组织 NAS 积分变化.....	52
讨 论	53
1 本实验造模评价.....	53
2 验证实验与均匀设计筛选实验的综合分析.....	53
结论和展望	55
缩 略 词 表	57
参 考 文 献	58
致 谢	65
附 录	66

Contents

Abstract in Chinese	I
Abstract in English	III
Introduction	1
1 Cognition of modern medicine on Non-alcoholic fatty liver disease	1
1.1 Summary of Non-alcoholic fatty disease	1
1.2 Pathological mechanism of Non-alcoholic fatty disease	2
1.3 Treatment of Non-alcoholic fatty disease	4
2 Cognition of Traditional Chinese Medicine on Non-alcoholic fatty liver disease	4
2.1 Etiology,pathogenesis and syndrome differentiation of Non-alcoholic fatty liver disease.....	4
2.2 Chinese medicine prescription treatment of Non-alcoholic fatty liver disease	5
2.3 Study on the effective components of Chinese medicine prescription	6
3 The treatment of Non-alcoholic fatty liver disease by chlorogenic acid and geniposide	7
3.1 The pharmacological effect of Chlorogenic acid on Non-alcoholic fatty liver disease	7
3.2 The pharmacological effect of geniposide on Non-alcoholic fatty liver disease	8
3.3 Preparations of our experiment	8
4 Uniform design could screen dosage of Chinese medicine effective components	9
Part I The experiment of screening the optimal dosage proportion of chlorogenic acid and geniposide on the basis of uniform design .	10
Materials and Methods	11
1 Materials	11
1.1 Animals	11

1.2 Medicines	11
1.3 Animal feed	11
1.4 Main reagents	11
1.5 Main instruments	12
1.6 Other equipment and consumables	12
2 Methods.....	12
2.1 Models.....	12
2.2 Grouping by uniform design	13
2.3 Medicines of experiment.....	14
2.4 Methods of sample extraction	14
2.5 Detection of liver TG	14
2.5.1 Sample preparation of liver tissue homogenate	14
2.5.2 Detection of liver TG content(Enzymic method)	14
2.6 Detection of serum lipid metabolism indexes.....	15
2.6.1 Detection of serum CHO content(Enzymic method).....	15
2.6.2 Detection of serum LDL-C content(Selective precipitation method).....	16
2.6.3 Detection of serum HDL-C content(Selective precipitation method)	17
2.7 Detection of serum inflammation injury indexes.....	17
2.7.1 Detection of serum ALT activity(Reitman-Frankel method)	17
2.7.2 Detection of serum AST activity(Reitman-Frankel method)	19
2.8 HE stain of hepatic tissue.....	19
2.9 Statistical analysis	20
Results	21
1 Assessment of general situation in each group	21
2 Body weight,liver weight and fat weight in each group	21
3 Liver index in each group	22
4 Liver appearance of normal group and model group.....	22
5 Pathology of hepatic tissue of normal group and model group	23
6 Results of lipid metabolism indexes in each group	23
7 Results of serum inflammation injury indexes in each group.....	25
8 Analysis of uniform design screening experiment.....	26
8.1 Multiple stepwise regression and analysis of liver TG as dependent variable	

.....	26
8.2 Multiple stepwise regression and analysis of serum ALT as dependent variable.....	28
8.3 Multiple stepwise regression and analysis of serum AST as dependent variable.....	29
8.4 Multiple stepwise regression and analysis of serum CHO as dependent variable.....	30
8.5 Multiple stepwise regression and analysis of serum LDL-C as dependent variable.....	31
8.6 Multiple stepwise regression and analysis of serum HDL-C as dependent variable.....	32
8.7 Multiple stepwise regression and analysis of body weight as dependent variable.....	33
8.8 Multiple stepwise regression and analysis of liver weight as dependent variable.....	34
8.9 Multiple stepwise regression and analysis of fat weight as dependent variable.....	35
8.10 Multiple stepwise regression and analysis of liver index as dependent variable.....	35
8.11 Comprehensive analysis of each index regression result in uniform design screening experiment	35
Discussion.....	37
1 Thinking of Non-alcoholic fatty liver disease animal model establishment.....	37
2 Connotation of compatibility of Chinese medicine prescription	38
3 Research methods of effective component of Chinese medicine prescription.....	39
4 Analysis of the rationality about uniform design to study effective component of Chinese medicine prescription.....	40
5 Using uniform design to screen the optimal dosage proportion of chlorogenic acid and geniposide.....	41
 Part II Verification experiment of the chlorogenic acid-geniposide optimal dosage proportion provided by uniform design screening. .	43
Materials and Methods.....	43
1 Materials	43
1.1 Animals	43

Degree papers are in the “[Xiamen University Electronic Theses and Dissertations Database](#)”.

Fulltexts are available in the following ways:

1. If your library is a CALIS member libraries, please log on <http://etd.calis.edu.cn/> and submit requests online, or consult the interlibrary loan department in your library.
2. For users of non-CALIS member libraries, please mail to etd@xmu.edu.cn for delivery details.